Literature DB >> 23165448

Decreasing colectomy rates for ulcerative colitis: a population-based time trend study.

Gilaad G Kaplan1, Cynthia H Seow, Subrata Ghosh, Natalie Molodecky, Ali Rezaie, Gordon W Moran, Marie-Claude Proulx, James Hubbard, Anthony MacLean, Donald Buie, Remo Panaccione.   

Abstract

OBJECTIVES: Colectomy rates for ulcerative colitis (UC) have been inconsistently reported. We assessed temporal trends of colectomy rates for UC, stratified by emergent vs. elective colectomy indication.
METHODS: From 1997 to 2009, we identified adults hospitalized for a flare of UC. Medical charts were reviewed. Temporal changes were evaluated using linear regression models to estimate the average annual percent change (AAPC) in surgical rates. Logistic regression analysis compared: (i) UC patients responding to medical management in hospital to those who underwent colectomy; (ii) UC patients who underwent an emergent vs. elective colectomy; and (iii) temporal trends of drug utilization.
RESULTS: From 1997 to 2009, colectomy rates significantly dropped for elective colectomies with an AAPC of -7.4% (95% confidence interval (CI): -10.8%, -3.9%). The rate of emergent colectomies remained stable with an AAPC of -1.4% (95% CI: -4.8%, 2.0%). Azathioprine/6-mercaptopurine prescriptions increased from 1997 to 2009 (odds ratio (OR)=1.15; 95% CI: 1.09-1.22) and infliximab use increased after 2005 (OR=1.68; 95% CI: 1.25-2.26). A 13% per year risk adjusted reduction in the odds of colectomy (OR=0.87; 95% CI: 0.83-0.92) was observed in UC patients responding to medical management compared with those who required colectomy. Emergent colectomy patients had a shorter duration of flare (<2 weeks vs. 2-8 weeks, OR=5.31; 95% CI: 1.58-17.81) and underwent colectomy early after diagnosis (<1 year vs. 1-3 years, OR=5.48; 95% CI: 2.18-13.79).
CONCLUSIONS: From 1997 to 2009, use of purine anti-metabolites increased and elective colectomy rates in UC patients decreased significantly. In contrast, emergent colectomy rates were stable, which may have been due to rapid progression of disease activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165448     DOI: 10.1038/ajg.2012.333

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  50 in total

1.  Trends in Colectomies for Colorectal Neoplasms in Ulcerative Colitis: a National Inpatient Sample Database Analysis over Two Decades.

Authors:  Alexander Ni; Mohammed Al-Qahtani; Ebram Salama; Daniel Marinescu; Maria Abou Khalil; Julio Faria; Nancy Morin; Gabriela Ghitulescu; Carol-Ann Vasilevsky; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2020-06-15       Impact factor: 3.452

2.  Infliximab or ciclosporin for acute severe ulcerative colitis?

Authors:  Ashwin N Ananthakrishnan
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-06-21

3.  Ulcerative colitis-associated hospitalization costs: a population-based study.

Authors:  Stephanie Coward; Steven J Heitman; Fiona Clement; James Hubbard; Marie-Claude Proulx; Scott Zimmer; Remo Panaccione; Cynthia Seow; Yvette Leung; Indraneel Datta; Subrata Ghosh; Robert P Myers; Mark Swain; Gilaad G Kaplan
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-16

4.  Colectomy is a risk factor for venous thromboembolism in ulcerative colitis.

Authors:  Gilaad G Kaplan; Allen Lim; Cynthia H Seow; Gordon W Moran; Subrata Ghosh; Yvette Leung; Jennifer Debruyn; Geoffrey C Nguyen; James Hubbard; Remo Panaccione
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

5.  Clostridium difficile infection worsens the prognosis of ulcerative colitis.

Authors:  María E Negrón; Herman W Barkema; Kevin Rioux; Jeroen De Buck; Sylvia Checkley; Marie-Claude Proulx; Alexandra Frolkis; Paul L Beck; Levinus A Dieleman; Remo Panaccione; Subrata Ghosh; Gilaad G Kaplan
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

6.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

7.  Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Authors:  Matthew C Choy; Dean Seah; David M Faleck; Shailja C Shah; Che-Yung Chao; Yoon-Kyo An; Graham Radford-Smith; Talat Bessissow; Marla C Dubinsky; Alexander C Ford; Leonid Churilov; Neville D Yeomans; Peter P De Cruz
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

Review 8.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

9.  Outcomes for Ulcerative Colitis With Delayed Emergency Colectomy Are Worse When Controlling for Preoperative Risk Factors.

Authors:  Ira L Leeds; Margaret H Sundel; Alodia Gabre-Kidan; Bashar Safar; Brindusa Truta; Jonathan E Efron; Sandy H Fang
Journal:  Dis Colon Rectum       Date:  2019-05       Impact factor: 4.585

10.  Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.

Authors:  Hiromitsu Ban; Shigeki Bamba; Atsushi Nishida; Osamu Inatomi; Makoto Shioya; Ken-Ichiro Takahashi; Hirotsugu Imaeda; Masaki Murata; Masaya Sasaki; Tomoyuki Tsujikawa; Akira Andoh
Journal:  Exp Ther Med       Date:  2016-05-16       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.